Miconi Gianfranca, Palumbo Paola, Dehcordi Soheila Raysi, La Torre Cristina, Lombardi Francesca, Evtoski Zoran, Cimini Anna Maria, Galzio Renato, Cifone Maria Grazia, Cinque Benedetta
Department of Life, Health and Environmental Sciences, University of L'Aquila-Building Delta 6, Coppito, L'Aquila, 67100, Italy.
J Cell Biochem. 2015 May;116(5):864-76. doi: 10.1002/jcb.25043.
Recently, glioma stem cells have been identified as the main cause of glioma propagation and recurrence and a number of several cell markers have been indicated as putative GSC markers. In the present work, a retrospective study to evaluate the prognostic potential of ability to generate GSCs in our series of 15 glioblastoma patients is described. β-tubulin III, nestin, CD133, GFAP, and SOX-2 marker expression, both in primary GBM cultures and in respective glioblastoma stem cells (GSCs), was evaluated by flow cytometric analysis. Our results demonstrated various expression levels of these markers in both cell cultures; of note, only those cells expressing SOX-2 at greater than 30% levels were able to produce in vitro neurospheres. Moreover, statistical analysis revealed that the GSCs generation negatively affected overall survival (OS) (P = 0.000) and progression-free survival (PFS) (P = 0.001). In addition, a very poor OS (P = 0.000) and PFS (P = 0.000) were observed among patients whose tumors expressed Ki67, evaluated by immunohistochemistry, and showed the ability to generate in vitro GSCs. Overall, the results suggest that in vitro GSCs generation associated to the expression of Ki67 and SOX-2 may be useful to identify patients at risk of disease progression.
最近,胶质瘤干细胞已被确定为胶质瘤增殖和复发的主要原因,并且一些细胞标志物已被指出可能是胶质瘤干细胞标志物。在本研究中,描述了一项回顾性研究,以评估在我们的15例胶质母细胞瘤患者系列中产生胶质瘤干细胞的能力的预后潜力。通过流式细胞术分析评估β-微管蛋白III、巢蛋白、CD133、胶质纤维酸性蛋白(GFAP)和SOX-2标志物在原发性胶质母细胞瘤培养物和各自的胶质母细胞瘤干细胞(GSCs)中的表达。我们的结果表明这些标志物在两种细胞培养物中的表达水平各不相同;值得注意的是,只有那些SOX-2表达水平大于30%的细胞能够在体外产生神经球。此外,统计分析显示,胶质瘤干细胞的产生对总生存期(OS)(P = 0.000)和无进展生存期(PFS)(P = 0.001)有负面影响。此外,通过免疫组织化学评估肿瘤表达Ki67并显示出在体外产生胶质瘤干细胞能力的患者中观察到非常差的总生存期(P = 0.000)和无进展生存期(P = 0.000)。总体而言,结果表明与Ki67和SOX-2表达相关的体外胶质瘤干细胞产生可能有助于识别有疾病进展风险的患者。